The National Institute for Health and Care Excellence (NICE) has issued a second draft guidance not recommending the use of Revlimid for myeloma patients at first relapse who have previously received Velcade® and who are not eligible for high-dose therapy and autologous stem cell transplantation. The appraisal consultation document has outlined that Revlimid is not considered to be cost-effective for use on the NHS and that there is a lack of clinical trial evidence on its use in this patient group.

Read the full article »